BioPharma Resources

Drug Trial Radar · NCT07221188

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,250

Planned (sponsor's estimate)

Start

Dec 12, 2025

Primary completion

Mar 24, 2028

Study completion Mar 24, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

  • Efimosfermin AlfaDrug

    Efimosfermin Alfa will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severityTime frame: At Week 52
  2. Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severityTime frame: At Week 52
  3. Number of participants with Grade 3 and Grade 4 laboratory abnormalitiesTime frame: At Week 52

Locations

66 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Arcadia, California · Recruiting

  • GSK Investigational Site

    Covina, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    San Diego, California · Recruiting

  • GSK Investigational Site

    Santa Maria, California · Recruiting

  • GSK Investigational Site

    Van Nuys, California · Recruiting

  • GSK Investigational Site

    Boynton Beach, Florida · Recruiting

  • GSK Investigational Site

    Cape Coral, Florida · Recruiting

  • GSK Investigational Site

    Clermont, Florida · Recruiting

  • GSK Investigational Site

    Doral, Florida · Recruiting

  • GSK Investigational Site

    Fort Myers, Florida · Recruiting

  • GSK Investigational Site

    Hialeah, Florida · Recruiting

  • GSK Investigational Site

    Homestead, Florida · Recruiting

  • GSK Investigational Site

    Inverness, Florida · Recruiting

  • GSK Investigational Site

    Jacksonville, Florida · Recruiting

  • GSK Investigational Site

    Kissimmee, Florida · Recruiting

  • GSK Investigational Site

    Lakeland, Florida · Recruiting

  • GSK Investigational Site

    Maitland, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

  • GSK Investigational Site

    Ocala, Florida · Recruiting

  • GSK Investigational Site

    Palmetto Bay, Florida · Recruiting

  • GSK Investigational Site

    Sarasota, Florida · Recruiting

  • GSK Investigational Site

    Topeka, Kansas · Recruiting

  • GSK Investigational Site

    Marrero, Louisiana · Recruiting

  • GSK Investigational Site

    Springfield, Missouri · Recruiting

  • GSK Investigational Site

    St Louis, Missouri · Recruiting

  • GSK Investigational Site

    St Louis, Missouri · Recruiting

  • GSK Investigational Site

    Jersey City, New Jersey · Recruiting

  • GSK Investigational Site

    East Syracuse, New York · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Morehead City, North Carolina · Recruiting

  • GSK Investigational Site

    Akron, Ohio · Recruiting

  • GSK Investigational Site

    Springboro, Ohio · Recruiting

  • GSK Investigational Site

    Chattanooga, Tennessee · Recruiting

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.